MCRB Rentabilitas dodolan reged Seres

Simbol resmi perusahaan Seres (MCRB)

The change in gross margin for Seres Therapeutics (MCRB) demonstrates business efficiency, where the value -35.80 captures the metric level. Seres Therapeutics generates revenue from treating patients with intestinal infections through the sale of innovative capsules. Primary income is based on the sale of the drug VOWST to combat recurrences. The firm is currently revising its portfolio strategy, which creates specific risks characteristic of the biotechnology sector.

MCRB Rentabilitas reged Seres Therapeutics, Inc. (04.07.2022 - 20.11.2026)

Rincian analitis lan laporan data perusahaan Seres Therapeutics (MCRB)

- nilai saham lan prakiraan konsensus rega:
Pambiji fundamental:MCRB Seres Therapeutics Inc.
Produk mawa merek Seres Therapeutics, Inc

A conservative investor assesses business resilience through the ability to generate profit over direct costs. This metric calculates the portion of revenue remaining after production costs, which in the historical gross margin of Seres Therapeutics (MCRB) reflects the commercialization efficiency of the drug VOWST and the scaling potential of microbiome therapy, determining the overall investment attractiveness of the company during its active growth phase.